Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, and pre-exposure prophylaxis (PrEP) for HIV prevention for persons who inject opioids accessing syringe services programs (SSPs), as part of a comprehensive harm reduction program, and assess the acceptability and feasibility of using telemedicine to implement the program. The initial visit will be conducted in person or remotely via telemedicine given COVID-19 protocols at the SSP sites in Charlotte and Wilmington, North Carolina (NC); follow-up visits will be conducted via telemedicine.
Description: Defined as self-reported opioid use on ≤4 days in the past month and/or 2 or more consecutive negative urine tests.
Measure: Proportion who demonstrate no or minimal opioid use. Time: 3 monthsDescription: Defined as self-reported opioid use on ≤4 days in the past month and/or 2 or more consecutive negative urine tests.
Measure: Proportion who demonstrate no or minimal opioid use. Time: 6 monthsDescription: Measured via negative HIV test.
Measure: Proportion who remain HIV negative. Time: 3 monthsDescription: Measured via negative HIV test.
Measure: Proportion who remain HIV negative. Time: 6 monthsDescription: Defined as the proportion who remain on treatment (MOUD or PrEP).
Measure: Persistence in care Time: 3 monthsDescription: Defined as the proportion who remain on treatment (MOUD or PrEP).
Measure: Persistence in care Time: 6 monthsDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method)
Measure: Ease/difficulty of visiting a SSP to meet with a provider via telemedicine Time: 1 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant over time (qualitative method)
Measure: Ease/difficulty of visiting a SSP to meet with a provider via telemedicine Time: 6 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method)
Measure: Ease/difficulty of accessing the telemedicine video platform Time: 1 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences of each participant (qualitative method)
Measure: Perceptions of medical care quality via a telemedicine video platform Time: 6 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant (qualitative method)
Measure: Participant satisfaction with the program Time: 1 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)
Measure: Participant satisfaction with the program Time: 6 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant (qualitative method)
Measure: Participant perceived usefulness of the program Time: 1 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)
Measure: Participant perceived usefulness of the program Time: 6 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)
Measure: Motivators and barriers affecting program persistence Time: 6 monthDescription: Exploratory method, conducted in the form of individual interviews to document the personal experiences and opinions of each participant over time (qualitative method)
Measure: Motivators and barriers affecting medication adherence and persistence Time: 6 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports